Heron Therapeutics v. Qilu Pharmaceutical: 13-Patent Aprepitant Dispute Dismissed in Delaware
Heron Therapeutics filed suit in Delaware against Qilu Pharmaceutical over 13 patents protecting Cinvanti®, its injectable aprepitant emulsion for chemotherapy-induced nausea. The case was dismissed after 126 days — before substantive merits proceedings concluded — leaving the competitive landscape for generic aprepitant emulsion formulations in flux.
13-Patent Cinvanti® Enforcement Action Ends Before Merits Adjudication
On July 3, 2025, Heron Therapeutics, Inc. filed a patent infringement complaint in the District of Delaware against Qilu Pharmaceutical Co., Ltd., Qilu Pharmaceutical (Hainan) Co., Ltd., and Qilu Pharma, Inc. The suit asserted 13 U.S. patents covering injectable emulsion formulations of aprepitant — the active ingredient in Heron’s branded antiemetic product Cinvanti® (130 mg/18 mL, 7.2 mg/mL). The case was assigned to Judge William C. Bryson, a Federal Circuit judge sitting by designation — a profile typically associated with technically complex pharmaceutical patent disputes.
The case was terminated on November 6, 2025, 126 days after filing, on the basis of case dismissal. The public docket records a stipulation extending Qilu’s response and invalidity contention deadlines — suggesting initial procedural cooperation between the parties — but the record does not specify whether the ultimate dismissal was entered with or without prejudice. The distinction is commercially significant: a with-prejudice dismissal would bar refiling, while a without-prejudice dismissal leaves the door open to renewed enforcement.
A resolution in 126 days — before Qilu’s invalidity contentions were even due — is notably swift for a 13-patent pharmaceutical infringement case in Delaware, and is consistent with a negotiated resolution or licensing agreement reached in parallel with the litigation. The absence of a trial date, claim construction order, or merits ruling means the validity and scope of Heron’s aprepitant patent portfolio remain untested by this proceeding. What drove the early termination remains unknown from the public record alone.
Filing to Case Dismissed in 126 days
126 days — resolved faster than the median ANDA-related patent case in Delaware, which typically exceeds 18 months
Case dismissed: what the termination means for both parties
Dismissal without a merits ruling — what that means
A case dismissal at this early stage — before claim construction, summary judgment, or trial — means the court issued no ruling on infringement, validity, or enforceability of Heron’s 13 patents. The public record does not specify whether the dismissal was with or without prejudice. This procedural posture is common where parties reach a commercial resolution, enter a licensing arrangement, or agree to stay proceedings pending regulatory developments.
No merits adjudicationWith or without prejudice? The public record is silent
The legal significance of this dismissal depends entirely on whether it was entered with or without prejudice — a distinction the public docket does not resolve. Dismissal with prejudice would permanently bar Heron from re-asserting these patents against Qilu’s aprepitant product in a new action. Dismissal without prejudice would preserve Heron’s right to refile. Until the order is available, practitioners should treat the enforceability posture of these 13 patents against Qilu as unresolved.
Prejudice status unknownQilu avoids merits exposure — for now
Qilu’s invalidity contentions had not yet been served when the case closed, meaning the Chinese generic manufacturer avoided substantive engagement on the validity of Heron’s aprepitant patent portfolio. No court finding favours or disfavours Qilu’s product going forward. However, if the dismissal was without prejudice, Qilu remains exposed to re-litigation and should monitor Heron’s enforcement activity and any ANDA-related 30-month stay implications carefully.
No validity findingGeneric aprepitant emulsion market entry remains uncertain
With 13 patents asserted and no merits ruling, the freedom-to-operate landscape for injectable aprepitant emulsion formulations remains legally unsettled. Competitors eyeing this space — whether through ANDA or 505(b)(2) pathways — cannot rely on this dismissal as evidence of patent vulnerability. Heron’s portfolio, spanning formulation, method-of-use, and composition patents, retains full presumption of validity. The swift resolution may signal a licensing deal, but no such terms are publicly disclosed.
FTO landscape unsettledFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Heron Therapeutics, Inc. | Company | Specialty pharmaceutical company — holder of US10624850B2 and 12 further Cinvanti® patentsSearch in Eureka ↗ |
| Defendant | Qilu Pharmaceutical Co., Ltd. | Company | Chinese generic pharmaceutical manufacturer with U.S. commercial subsidiary Qilu Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jeremy A. Tigan | Attorney | Counsel for Heron Therapeutics, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Heron Therapeutics, Inc.Search in Eureka ↗ |
| Presiding judge | Judge William C. Bryson | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The verdict text reflects a procedural stipulation — an agreed extension of Qilu’s response and invalidity contention deadlines — rather than a substantive merits ruling. This is consistent with early-stage case management and does not indicate any admission of infringement or validity concession by either party. The case’s termination on a dismissal basis, without a claim construction order or summary judgment ruling, means neither party obtained a judicial determination on the merits of the 13 asserted aprepitant patents.
US10624850B2 and 12 further patents — injectable aprepitant emulsion formulations
The 13 patents asserted in this case collectively protect Heron’s Cinvanti® product — an injectable emulsion delivering 130 mg aprepitant in 18 mL (7.2 mg/mL) for intravenous administration to prevent chemotherapy-induced nausea and vomiting (CINV). The portfolio spans multiple application families filed between 2014 and 2024, covering formulation composition, emulsion stability, excipient selection, and methods of administration. This layered filing strategy — with application dates across nearly a decade — is consistent with life-cycle management of a branded injectable product facing generic entry pressure.
Aprepitant is an NK1 receptor antagonist with established clinical utility in CINV prophylaxis, and Cinvanti® represented a reformulation of the oral capsule (Emend®) into an injectable emulsion to avoid solubilising agents associated with adverse reactions. The breadth of this portfolio — 13 patents covering different technical aspects of the same product — materially raises the cost and complexity of any validity challenge, whether mounted through ANDA litigation, IPR petition, or district court invalidity counterclaim. Any generic or biosimilar developer targeting the injectable aprepitant emulsion space must navigate this full portfolio.
Should your team run an FTO against Heron’s aprepitant emulsion patent portfolio?
Any pharmaceutical company developing, manufacturing, or seeking regulatory approval for an injectable aprepitant emulsion formulation — whether through an ANDA, 505(b)(2), or NDA pathway — faces direct FTO exposure against Heron’s 13-patent portfolio. The absence of a merits ruling in this case means none of these patents has been judicially invalidated or found unenforceable. Product teams and regulatory affairs professionals should not treat the dismissal as a green light for market entry without a thorough claim-by-claim clearance analysis.
PatSnap Eureka’s FTO Search Agent enables R&D and IP teams to map claim scope across all 13 asserted patents simultaneously, identify prosecution history estoppel, and benchmark against prior art landscapes. With family members potentially pending in international jurisdictions, a Eureka-powered FTO analysis can surface related applications that may extend exclusivity beyond the U.S. portfolio. Early FTO work — before IND filing or ANDA submission — materially reduces downstream litigation risk in a space where Heron has demonstrated willingness to assert broadly.
Run a freedom-to-operate analysis on US10624850B2 to assess your product’s exposure
Run FTO in Eureka →Similar injectable pharmaceutical patent cases in Delaware District Court
Browse related pharmaceutical formulation patent infringement cases in the District of Delaware involving injectable drug products, ANDA litigation, and multi-patent assertions.
What this case signals for the injectable antiemetic IP landscape
A 13-patent assertion resolved in 126 days carries strategic signals for any pharmaceutical company tracking Cinvanti® or the broader aprepitant emulsion space.
13-patent portfolio assertions are a high-stakes deterrent strategy
Asserting 13 patents in a single complaint — covering formulation, composition, and method-of-use claims — signals that Heron has constructed overlapping layers of IP protection for Cinvanti®. This breadth makes invalidity challenges significantly more costly and time-consuming for generic entrants, and likely contributed to the case resolving before Qilu’s invalidity contentions were even due.
Swift dismissals in ANDA-adjacent cases often mask licensing activity
In pharmaceutical patent disputes involving branded-versus-generic dynamics, early dismissal in under 130 days before any claim construction order is strongly consistent with a negotiated licensing arrangement or market entry agreement. Practitioners monitoring Qilu’s commercialisation timeline for its aprepitant emulsion product should watch for regulatory approval signals and product launch activity.
Heron v Qilu — key questions answered
Heron Therapeutics asserted 13 U.S. patents in this action, including US10624850B2, US11744800B2, US12290520B2, US11173118B2, US9808465B2, US10953018B2, US9974793B2, US9974794B2, US12115254B2, US10500208B2, US12115255B2, US9561229B2, and US9974742B2. All patents relate to injectable aprepitant emulsion formulations covering Heron’s Cinvanti® product.
The public record does not state the reason for dismissal. The case closed on November 6, 2025, before claim construction or any merits ruling. The docket reflects a procedural stipulation extending Qilu’s response deadlines, which is consistent with ongoing negotiations. Early dismissal in pharmaceutical patent cases of this type typically suggests a licensing arrangement or commercial settlement, though no such terms are publicly disclosed.
The public record is silent on this point. The basis of termination is recorded as ‘Case Dismissed’ without specifying prejudice status. Dismissal with prejudice would bar Heron from re-asserting these patents against Qilu’s aprepitant product in a new action; dismissal without prejudice would preserve that right. Practitioners should not assume either outcome without reviewing the actual dismissal order.
Cinvanti® is Heron Therapeutics’ branded injectable emulsion containing 130 mg aprepitant in 18 mL (7.2 mg/mL), indicated for prevention of chemotherapy-induced nausea and vomiting. It reformulates the oral aprepitant (Emend®) into an intravenous emulsion. Qilu Pharmaceutical’s filing of a competing injectable aprepitant product application triggered Heron’s enforcement of its 13-patent portfolio in Delaware.
Judge William C. Bryson is a senior judge of the U.S. Court of Appeals for the Federal Circuit, sitting by designation in the District of Delaware. His assignment to technically complex pharmaceutical patent cases is consistent with Delaware’s practice of utilising Federal Circuit judges for high-complexity IP matters. His background in patent appellate law suggests the court anticipated technically demanding claim construction issues across the 13-patent portfolio.
PatSnap Eureka searches patents and litigation data to answer instantly.